The MAP2K5 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the MAP2K5 gene in a human B-lymphocyte background. This product provides a heterogeneous pool of gene-disrupted Raji cells, enabling robust assessment of MAP2K5 function in signal transduction and lymphoma biology. The polyclonal format captures diverse editing events across the population, offering a practical and genetically perturbed cellular model without clonal selection.
The host Raji cell line is an Epstein-Barr virus-positive Burkitt lymphoma B-lymphocyte model widely used in immunology and cancer research. Derived from a human B-cell malignancy, Raji cells maintain key features of B-lymphocyte biology, including surface immunoglobulin expression and susceptibility to apoptosis-inducing agents. Their rapid growth in suspension culture and well-characterized signaling networks make them an ideal platform for studying oncogenic kinase pathways and evaluating therapeutic agents in B-cell lymphoma.
MAP2K5 encodes a dual-specificity mitogen-activated protein kinase kinase that specifically phosphorylates and activates ERK5 (MAPK7) downstream of growth factor receptors such as EGFR and TrkA. The canonical signaling cascade involves upstream activation by Ras, Raf, MEKK2 (MAP3K2), and MEKK3 (MAP3K3), which converge on MAP2K5 to initiate ERK5-mediated phosphorylation of MEF2 transcription factors and induction of target genes like c-Fos and Cyclin D1. Scaffold proteins, including JIP1, facilitate complex assembly. This pathway mediates cellular responses to EGF and NGF, promoting proliferation, differentiation, and survival, and is frequently dysregulated in cancers.
In Burkitt lymphoma, MAP2K5?CERK5 signaling may contribute to the unchecked proliferation and apoptotic resistance characteristic of this aggressive B-cell malignancy. The Raji polyclonal knockout model thus provides a pertinent system for dissecting the role of this kinase module in lymphoma pathobiology. Disruption of MAP2K5 in this context enables researchers to interrogate how loss of ERK5 activation alters cell cycle progression, apoptotic threshold, and response to growth factor stimuli, potentially revealing vulnerabilities exploitable by targeted therapies.
The MAP2K5 Knockout Raji Polyclonal Cells support a variety of investigative applications, including functional genomics screening, validation of MAPK pathway inhibitors, and exploration of resistance mechanisms in B-cell lymphoma. Representative assays include Western blotting for MAP2K5 and phospho-ERK5 to confirm pathway disruption, RT?qPCR for transcriptional output, cell proliferation (MTT) and apoptosis (Annexin V/7?AAD) assays to assess growth and survival phenotypes, phospho?flow cytometry for signaling dynamics, and drug sensitivity profiling with MEK inhibitors. For further details, please contact Ascent Research.
